Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Biotechnology Stocks

A list of publicly traded biotechnology and biotech-related stocks and ETFs.
Thu, Feb 27th, 2025

Biotechnology (biotech) Stocks are publicly traded companies that develop pharmaceutical drugs used in the treatment of disease. You can use Barchart's Biotech Stocks list to find investment opportunities and compare stocks involved in this hot industry.

View Profiles of these companies.

  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Please wait...

Biotechnology Stocks News

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,962.75 (+0.11%)
STOK : 8.47 (+2.42%)
ACAD : 20.27 (+6.68%)
PHAT : 5.76 (-0.52%)
BIIB : 141.07 (+0.41%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.31 (-0.21%)
JNJ : 162.68 (-0.25%)
VRTX : 483.21 (+0.86%)
SNDX : 15.90 (+2.12%)
ABBV : 204.75 (+0.86%)
GERN : 1.6200 (+0.62%)
RHHBY : 41.4900 (-1.31%)
PFE : 26.19 (-0.87%)
NTLA : 11.60 (+7.41%)
BMY : 58.46 (+1.88%)
BIIB : 141.07 (+0.41%)
Artificial Pancreas Maker Beta Bionics Just Started Trading. Should You Buy BBNX Stock After Its IPO?

This healthcare technology company is guiding for revenue growth of 150% for Q4.

BBNX : 19.96 (-0.15%)
Verona Pharma Keeps Hitting New Highs

Summary Verona Pharma (VRNA) shows strong technical indicators with a 54.89% gain since 11/19, driven by Barchart's Trend Seeker buy signal. The company focuses on developing ensifentrine for respiratory...

VRNA : 68.19 (+7.35%)
Purdue Pharma and owners to pay $7.4 billion in settlement of lawsuits over the toll of OxyContin

Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller

Family who owns Purdue Pharma could pay up to $7.4 billion in latest settlement of lawsuits over the toll of OxyContin

Family who owns Purdue Pharma could pay up to $7.4 billion in latest settlement of lawsuits over the toll of OxyContin

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements